Paradigm BioCapital Advisors Reports 3.8% Stake in EyePoint Pharmaceuticals, Inc. (EYPT)

On May 15, 2026, Paradigm BioCapital Advisors LP filed a Schedule 13G/A with the SEC, reporting a 3.8% ownership stake in EyePoint Pharmaceuticals, Inc. (EYPT). The filing indicates that the reporting persons, which include Paradigm BioCapital Advisors LP (the Adviser), Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd., collectively hold 3,142,437 shares of common stock. Specifically, the International Fund directly holds 2,769,062 of these shares (3.3%), while the remaining shares are held via managed accounts. Senai Asefaw, as the managing member of the Adviser GP, may be deemed to share beneficial ownership of the total position. This amendment marks an increase from a previously reported 0.0% position as of the event date of March 31, 2026. The filing was made under Rule 13d-1(c), certifying that the shares were not acquired for the purpose of changing or influencing the control of the issuer. The calculation is based on 83,453,001 shares outstanding as of March 31, 2026.